Replimune Reports $86.7 Million Net Loss and Increased Operating Expenses for Q2 2025

Replimune Group, Inc. reported a net loss of $86.7 million for the three months ended June 30, 2025, compared to a net loss of $53.8 million for the same period in 2024. This represents a 61% increase in losses year-over-year, primarily driven by a significant rise in operating expenses, which totaled $90.4 million, up from $57.4 million in the prior year. The increase in operating expenses was largely attributed to higher research and development costs, which rose to $57.8 million from $43.0 million, and selling, general, and administrative expenses, which increased to $32.6 million from $14.4 million.

The company's total assets decreased to $469.5 million as of June 30, 2025, down from $551.3 million at the end of the previous fiscal quarter. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $97.4 million from $111.1 million, and a decrease in short-term investments, which dropped to $306.0 million from $372.7 million. Replimune's accumulated deficit also increased to $1.035 billion, reflecting ongoing investment in its clinical programs without any revenue generation, as the company has yet to commercialize any products.

Strategically, Replimune is focused on advancing its proprietary oncolytic immunotherapy product candidates, particularly RP1, RP2, and RP3. The company is conducting multiple clinical trials, including the IGNYTE trial for RP1, which is in collaboration with Bristol-Myers Squibb. However, the company faced a setback when the FDA issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 in July 2025, stating that the application could not be approved in its current form. Replimune plans to engage with the FDA to explore potential pathways for approval.

As of June 30, 2025, Replimune had cash and cash equivalents and short-term investments totaling $403.3 million, which the company believes will be sufficient to fund operations through at least the fourth quarter of 2026. The company anticipates continued operating losses as it invests in clinical trials and the development of its product candidates. Replimune's management has indicated that future funding may be necessary to support ongoing operations and development efforts, and the company may pursue additional equity offerings, debt financing, or collaborations to secure the required capital.